SWIXX WELCOMES RENAUD SERMONDADE AS CBDO AND GYORGY ENDES AS CHRO

Baar, Switzerland, November 12, 2026 – Swixx Biopharma AG of Baar, Switzerland, announced today the appointment of Renaud Sermondade as Chief Business Development Officer (CBDO) and Gyorgy Endes, MD, as Chief Human Resources Officer (CHRO). Both join the Executive Committee and report to Chief Executive Officer, Jean-Michel Lespinasse. The appointments support the company's next phase of growth and geographic expansion.

Renaud Sermondade brings more than 25 years of international experience across pharmaceuticals, drug delivery and strategy consulting, combining business development, partnership building and general management. He joins Swixx from Juvisé Pharmaceuticals, where he served as Chief Executive Officer. Previously, he was President of Aptar Injectables and Vice President & General Manager EMEA at Aptar Pharma, where he also held global responsibility for business development. Earlier, he held global and China leadership roles at Sanofi, built the MSD/Simcere joint venture in China as General Manager, and led business units and portfolio development at Bristol Myers Squibb in China and EMEA. He began his career with A.T. Kearney and Roland Berger.

Gyorgy Endes brings more than 30 years of international experience in human resources and commercial roles in the pharmaceutical industry, having worked across Europe, the USA and China. Most recently, he was Head of Human Resources at CSL Vifor, where he led the people and culture integration following Vifor Pharma's acquisition by CSL. Before that, he was Head of Human Resources at CSL Seqirus and Vice President, Global Head of Human Resources at CSL Behring. He previously held HR and commercial roles of increasing seniority at Johnson & Johnson, Celgene, Bristol-Myers Squibb, Egis and Eli Lilly. Gyorgy holds a medical degree from the University of Debrecen and an MBA from the Budapest University of Technology and Economics.

Jean-Michel Lespinasse, Chief Executive Officer of Swixx Biopharma, welcomed the new members of his senior team, **commenting:** "Swixx is growing fast, and so is our ambition to bring modern medicines to more patients in more markets. With Renaud, we are strengthening our position as the partner of choice for pharmaceutical and biotech companies. His experience in building partnerships, from global pharma to emerging markets, will be key as we expand our portfolio and our footprint.

With Gyorgy, we are investing in a dedicated people strategy at Executive Committee level. Our people have always been the engine of Swixx's success. Now we will reinforce talent management, development planning and succession, so that our colleagues can continue growing as the company does. I am delighted to welcome them both to the team."

Stuart Swanson, Head of Corporate Development, will continue to serve on the Swixx Biopharma Board and to provide strategic guidance.

About Swixx

Swixx is one of the largest commercialization platforms representing the portfolio of pharmaceutical companies in those markets in which they choose not to enter or decide to exit. Swixx group of companies and affiliates operates across multiple countries in Central and Eastern Europe, Greece, Eurasia and several CIS countries, the Middle East and Latin America. With presence in more than 50 countries, 2,100 employees and sales which exceeded 1.4 billion Euros in 2025, Swixx is one of the fastest-growing independent commercialization platforms for biopharma globally. Swixx has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and CNS therapy area talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com.





Swixx investor and partner inquiries:

Jean-Michel Lespinasse, CEO
bd.info@swixxbiopharma.com

Renaud Sermondade, Chief Business Development Officer
bd.info@swixxbiopharma.com

Swixx media inquiries:

Vedrana Sokac Brataljenovic, Public Affairs Director
vedrana.sokac@swixxbiopharma.com, Tel: +385 1 425 6086